ABT

Abbott Laboratories

102.71 USD

Last updated Nov 28, 13:06 UTC

Yesterday HIGH

$103.47

Yesterday LOW

$102.25

52w HIGH

$115.83

52w LOW

$89.67

EPS

1.14

PE

90.10

Next Earnings

Jan 24, 2024

Overview News Unusual Options Flow Insider Transactions Government Trades

Abbott Laboratories stock is up 10.44% since 30 days ago. The next earnings date is Jan 24, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 70% of the previous 49 November’s closed higher than October. In the last 10 Unusual Options Trades, there were 7 CALLs, 3 PUTs.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

22 Nov 20:35	21 Jun, 2024	80.00	CALL	50	199
24 Nov 15:53	16 Feb, 2024	125.00	PUT	53	0
24 Nov 16:23	17 Jan, 2025	95.00	CALL	18	400
24 Nov 16:32	24 Nov, 2023	100.00	CALL	100	520
24 Nov 17:00	16 Feb, 2024	130.00	PUT	19	0
27 Nov 15:51	01 Dec, 2023	98.00	CALL	123	294
27 Nov 15:51	01 Dec, 2023	98.00	CALL	49	294
27 Nov 15:51	01 Dec, 2023	98.00	CALL	70	294
27 Nov 17:22	17 Jan, 2025	120.00	PUT	25	450
27 Nov 20:57	15 Dec, 2023	90.00	CALL	85	435

Advanced Data Unlock

Abbott Laboratories discovers, develops, manufactures, and sells health care products. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases.

Stock Exchange

NYSE

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Green Oaks, United States Of America

Website

abbott.com

Vandana Singh

Wed Oct 18, 2023

Abbott Stock Gains On Q3 Performance, 10% Organic Diagnostics Revenue Growth, Raised Annual Outlook

Abbott Laboratories (NYSE: ABT) has reported Q3 FY23 adjusted EPS of $1.14, almost similar to $1.15 a year ago, beating the con
Benzinga Newsdesk

Wed Oct 18, 2023

Abbott Projects FY23 Adjusted EPS Of $4.42-$4.46 Versus Prior Guidance Of $4.30-$4.50 And Consensus Of $4.18
Benzinga Newsdesk

Wed Oct 18, 2023

Abbott Laboratories Q3 Adjusted EPS $1.14 Beats $1.04 Estimate, Sales $10.14B Beat $9.32B Estimate

Abbott Laboratories (NYSE:ABT) reported quarterly earnings of $1.14 per share which beat the analyst consensus estimate of $1.04 by 9.62 percent. This is a 0.87 percent decrease over earnings of $1.15 per share from the
Benzinga Insights

Wed Oct 18, 2023

Earnings Scheduled For October 18, 2023

Companies Reporting Before The Bell • Procter & Gamble (NYSE:PG) is expected to report quarterly earnings at $1.71 per share on revenue of $21.67 billion.
Benzinga Insights

Tue Oct 17, 2023

Abbott Laboratories's Earnings Outlook
Johnny Rice

Mon Oct 16, 2023

Amid Israel-Palestine And Ukraine Gas, Gold Up Big, Cathie Wood's ARKK Down Almost 4% - ETF Winners And Losers: Medium-Cap Returns
Benzinga Insights

Mon Oct 16, 2023

A Look Into Abbott Laboratories Inc's Price Over Earnings
Shanthi Rexaline

Mon Oct 16, 2023

Tesla, Netflix Grab Earnings Spotlight This Week As Analysts Divided On Q3 Reporting Season: What's On Investors' Radar?

While analysts look forward to the unfolding reporting season with guarded optimism, they are skeptical regarding forward guidance.
Piero Cingari

Fri Oct 13, 2023

Israel-Hamas War Shakes Middle East, Inflation Reawakens, Oil Surges: The Week In The Markets

Higher-than-expected inflation data this week caught markets off guard, and the Israel-Hamas conflict is sending the markets running to safer assets.
Johnny Rice

Thu Oct 12, 2023

As Israel-Palestine Conflict Escalates, Gold Ticks Up - ETF Winners And Losers: Medium-Cap Returns

We performed a screening of medium-cap ETFs, defined as having Assets Under Management (AUM) between $2 billion and $10 billion – to determine what funds had the largest positive and negative returns on the week, according to data from etfdb.com. Only non-leveraged funds were considered.